Clinical efficacy and safety of Irbesartan combined with recombinant human brain natriuretic peptide in the treatment of congestive heart failure
Objective To investigate the clinical treatment and safety of Irbesartan combined with recombinant human brain natriuretic peptide in patients with congestive heart failure. Methods A total of 98 patients with congestive heart failure were enrolled in this study from June 2015 to November 2016 in Lueyang County People's Hospital. They were randomly divided into control group and observation group, 49 cases in each group.The control group was given Irbesartan, and the observation group was added with human brain natriuretic peptide on the basis of the control group. Results The effective rate of the observation group was 95.92%, the control group was 83.67%, and there was significant difference between two groups (P<0.05); the level of the antidiuretic hormone and endothelin-1 and serum norepinephrine of the two groups were significantly decrease than before treatment (P<0.05); antidiuretic hormone and endothelin-1 and serum norepinephrine epinephrine of patients in the observation group were decreased significantly compared with the control group (P<0.05); there was no statistical significance in adverse reaction rate between the observation group and the control group. Conclusion The treatment of Irbesartan combined with recombinant human brain natriuretic peptide in patients with congestive heart failure is effective and safe.
Irbesartanrecombinant human brain natriuretic peptidecongestive heart failureclinical efficacysafety
NETL
NSTL
万方数据
维普
